Agenus Inc financial data

Symbol
AGEN on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3 Forbes Road, Lexington, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
ANTIGENICS INC /DE/ (to 1/5/2011)
Latest financial report
10-K - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 25.1 % -65.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.3M shares -94%
Common Stock, Shares, Outstanding 21.7M shares
Entity Public Float 352M USD -39.7%
Common Stock, Value, Issued 236K USD +19.8%
Weighted Average Number of Shares Outstanding, Basic 21.5M shares +20%
Weighted Average Number of Shares Outstanding, Diluted 21.5M shares +20%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 103M USD -33.8%
Cost of Revenue 486K USD -84.4%
Research and Development Expense 156M USD -33.7%
General and Administrative Expense 71.9M USD -8.71%
Operating Income (Loss) -120M USD +24.5%
Nonoperating Income (Expense) 5.83M USD +15657%
Earnings Per Share, Basic -10.6 USD/shares +23%
Earnings Per Share, Diluted -10.6 USD/shares +23%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40.4M USD -46.9%
Cash, Cash Equivalents, and Short-term Investments 40.4M USD -46.9%
Accounts Receivable, after Allowance for Credit Loss, Current 407K USD -98.4%
Other Assets, Current 2.42M USD +1.81%
Assets, Current 45.6M USD -59.5%
Property, Plant and Equipment, Net 120M USD -9.99%
Operating Lease, Right-of-Use Asset 27.3M USD -7.76%
Intangible Assets, Net (Excluding Goodwill) 3.38M USD -23.5%
Goodwill 24.1M USD -2.55%
Other Assets, Noncurrent 5.83M USD -37.5%
Assets 226M USD -27.9%
Accounts Payable, Current 61.5M USD +0.04%
Accrued Liabilities, Current 35M USD -22.8%
Contract with Customer, Liability, Current 31K USD
Liabilities, Current 221M USD -13.5%
Contract with Customer, Liability, Noncurrent 1.14M USD 0%
Operating Lease, Liability, Noncurrent 54.6M USD -12.7%
Other Liabilities, Noncurrent 738K USD -86.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.4M USD -46.4%
Retained Earnings (Accumulated Deficit) -2.18B USD -11.6%
Stockholders' Equity Attributable to Parent -326M USD -104%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -306M USD -107%
Liabilities and Equity 226M USD -27.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD +34.7%
Net Cash Provided by (Used in) Financing Activities 14.8M USD -73.6%
Net Cash Provided by (Used in) Investing Activities 229K USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 23.6M shares +19.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -23.3M USD -67.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 667K USD -19.6%
Deferred Tax Assets, Valuation Allowance 401M USD +6.64%
Deferred Tax Assets, Gross 417M USD +6.23%
Operating Lease, Liability 57M USD -12.4%
Payments to Acquire Property, Plant, and Equipment 35K USD -98.1%
Lessee, Operating Lease, Liability, to be Paid 101M USD -15%
Property, Plant and Equipment, Gross 193M USD -1.39%
Operating Lease, Liability, Current 2.45M USD -5.45%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.3M USD -17.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.61M USD -12.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 44.4M USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.52M USD -13.5%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.23M USD -5.91%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.77M USD -13.3%
Additional Paid in Capital 1.86B USD +3.43%
Deferred Tax Assets, Net of Valuation Allowance 15.3M USD -3.68%
Share-based Payment Arrangement, Expense 27.3M USD +22.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%